ARKG250110P17000
- 0.00
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Recursion Pharmaceuticals Analyst Ratings
Cathie Wood Sells 36K Shares of Her Own Bitcoin Backed ARKB to Start off 2025
"Nvidia Magic" Strikes Again! Exploring Nvidia's Latest AI Investment Landscape
Beam Upgraded by Bernstein Ahead of AATD Data
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Cathie Wood Meets Moomoo: Exclusive Insights for Our Community
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Trending Industry Today: ARK Genomic Revolution ETF Leads Gains In ARK ETFs Stocks
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Trending Industry Today: ARK Genomic Revolution ETF Leads Losses In ARK ETFs Stocks
Adaptive Biotechnologies Analyst Ratings
Tempus Signs Agreements For In-Network Provider Status With Blue Cross Blue Shield Of Illinois, Blue Shield Of California And Avalon Healthcare Solutions
Tempus AI Announced CMS Decision That Will Allow Reimbursement Assessments Of Cardiax Dysfunctions Using Tempus ECG-AF Algorithm.
Twist Bioscience Analyst Ratings
Natera Analyst Ratings
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites